Patients with Uveal Melanoma Tested with DecisionDx®-UM Report Gaining Value from Test Results In Study Conducted In Collaboration with the Melanoma Research Foundation’s CURE OM Initiative
Data shows patients surveyed had low decision regret1 after testing with DecisionDx®-UM, regardless of whether their uveal melanoma tumor was at high or low risk of metastasis
The poster, titled “Uveal Melanoma Patient Attitudes Towards Prognostic Testing Using Gene Expression Profiling” and presented by
“Most patients impacted by the rare but quite deadly disease, uveal melanoma, want and expect to play an active role in their care to ensure the best possible outcome,” said Williams. “We believe the survey data supported this sentiment and found that regardless of their overall prognosis, patients value the information provided by their DecisionDx-UM test results.”
Study highlights:
- An online questionnaire was distributed by the Melanoma Research Foundation’s CURE OM (Ocular Melanoma) initiative to capture anonymous information regarding patient-reported experiences following prognostic testing.
- Patients were asked questions regarding the decision to undergo prognostic testing and the extent to which they felt decision regret.
-
Of the 177 survey participants,
90% reported wanting prognostic information at diagnosis. - Of the patients who received prognostic testing with DecisionDx-UM, there was no significant difference in decision regret levels among those receiving a low- (Class 1A), intermediate- (Class 1B) or high-risk (Class 2) test result (Kruskal-Wallis rank sum test, X2=4.1, p=0.13).
-
Patients tested with DecisionDx-UM reported gaining value from their test result, including:
- Increased knowledge and understanding of their disease
- More personalized treatment options
- Information relevant to life planning
- Relief from uncertainty about the future
About DecisionDx®-UM
DecisionDx-UM is Castle Biosciences’ 15-gene expression profile (GEP) test that uses an individual patient’s tumor biology to predict individual risk of metastasis in patients with uveal melanoma. DecisionDx-UM is the standard of care in the management of newly diagnosed uveal melanoma in the majority of ocular oncology practices in
It is estimated that nearly 8 in 10 patients diagnosed with uveal melanoma in the
More information about the test and disease can be found at www.CastleTestInfo.com.
About
Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of
1Decision Regret Scale: AM O’Connor, 1996
View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005296/en/
Investor Contact:
czuckero@castlebiosciences.com
Media Contact:
amarshall@castlebiosciences.com
Source: